EA
CORT icon

Emerald Advisers’s Corcept Therapeutics CORT Stock Holding History

Emerald Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.1M Buy
748,325
+542,767
+264% +$32.8M 1.53% 9
2026
Q1 		$8.29M Sell
205,558
-27,181
-12% -$1.02M 0.26% 108
2025
Q4 		$8.1M Buy
232,739
+287
+0.1% +$22.5K 0.25% 107
2025
Q3 		$19.3M Sell
232,452
-9,601
-4% -$695K 0.62% 67
2025
Q2 		$17.8M Buy
242,053
+179,871
+289% +$13M 0.65% 61
2025
Q1 		$7.1M Buy
+62,182
New +$3.78M 0.32% 99

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Advisers's CORT Position: Q2 2026 in Review

Emerald Advisers increased its Corcept Therapeutics (CORT) stake by 264% in Q2 2026, buying an estimated $32.8M and bringing the position to 748,325 shares worth $65.1M. The position accounts for 1.53% of the portfolio, ranked #9.

Emerald Advisers first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Emerald Advisers held 748,325 shares of Corcept Therapeutics worth $65.1M as of Q2 2026.
  • Emerald Advisers bought 542,767 Corcept Therapeutics shares in Q2 2026, an estimated $32.8M.
  • Corcept Therapeutics made up 1.53% of Emerald Advisers's portfolio in Q2 2026, its #9 holding.
  • Emerald Advisers first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.